3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
65
Neoplasms
56
Prostatic Neoplasms
44
Lung Neoplasms
35
Colorectal Neoplasms
35
Carcinoma, Non-Small-Cell Lung
24
Pancreatic Neoplasms
21
Hematologic Neoplasms
19
Head and Neck Neoplasms
16
Neoplasm Metastasis
15
Urinary Bladder Neoplasms
12
Ovarian Neoplasms
11
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Motor Activity
10
Triple Negative Breast Neoplasms
9
Multiple Myeloma
9
Colonic Neoplasms
9
Melanoma
8
Glioma
8
Anxiety Disorders
8
Uterine Cervical Neoplasms
7
Hematopoietic and Lymphatic System Neoplasm
7
Glioblastoma
7
Gastrointestinal Neoplasms
7
Esophageal Neoplasms
7
Anatomic Stage I Breast Cancer AJCC v8
7
Smoking Cessation
6
Sarcoma
6
Rectal Neoplasms
6
Interventions
Bendamustine Hydrochloride
3
fludarabine
2
Cyclophosphamide
2
Brentuximab Vedotin
2
pembrolizumab
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
Standard of Care
1
Rituximab
1
Radiotherapy
1
Melphalan
1
Etoposide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphatic Diseases
×
Standard of Care
×
Clear all
NCT04853095
2022-12-16
PerFix
University Hospital Olomouc
Phase NA
Completed
260 enrolled